Real-World Data on Risankizumab and Psoriatic Arthritis Prevention in Psoriasis

Source Summary

Saakshi Khattri, MD, discusses how real-world comparative effectiveness data suggest a potential class-level signal for risankizumab and IL-23 inhibition in reducing the risk of psoriatic arthritis among patients with psoriasis.